FY23 Corporate Strategy and Sustainability Journey

While we continue to drive productivity, we are also investing for future growth Gross Margin: Increase driven by high margin new product sales & higher government incentives SG&A: Investing in brands and digital capabilities 56.7% 54.2% 53.8% 54.3% 53.1% FY19 FY20 FY21 FY22 FY23 R&D: Focus on high value generics including biosimilars 10.1% 8.8% 8.7% 8.2% 7.9% 31.7% 28.7% 28.8% 29.0% 27.7% 4.9k cr ($ 0.6 bn) 5.0k cr ($ 0.6 bn) 5.5k cr ($ 0.7 bn) 6.2k cr ($ 0.8 bn) 6.8k cr ($ 0.8 bn) FY19 FY20 ■SG&A cost FY21 FY22 % to Sales FY23 Capital expenditure: Selectively investing to augment capabilities, including injectables and biosimilars 1.5k cr 1.6k cr ($ 0.2 bn) 1.5k cr ($ 0.2 bn) 1.7k cr ($ 0.2 bn) 1.7k cr ($ 0.2 bn) 1.9k cr ($0.2 bn) 1.0k cr ($ 0.2 bn) 1.1k cr ($ 0.1 bn) 0.7k cr ($ 0.1 bn) 0.5k cr ($ 0.1 bn) ($ 0.1 bn) FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 ■R&D cost % to Sales USD/INR = 82.19 (rate as on 31st Mar, 2023) 10

View entire presentation